Psychotropic discontinuation leading to an NMS‐like condition
Open accessAbstract
Abstract Neuroleptic malignant syndrome (NMS) is a potentially life‐threatening condition, which can occur as a complication in patients taking antipsychotic medications. Drs Kurien and Vattakatuchery present the case of a patient with paranoid schizophrenia who developed NMS‐like symptoms following abrupt discontinuation of clozapine and venlafaxine.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital
Pope, H. G., Keck, P. E., & McElroy, S. L. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.10.1227 · Cited by 303 · see citing works
Emergence of Adverse Events Following Discontinuation of Treatment With Extended-Release Venlafaxine
D, M. F. M., Mulroy, R., Alpert, J. E., Nierenberg, A. A., & Rosenbaum, J. F. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.12.1760 · Cited by 198 · see citing works
Neuroleptic Malignant Syndrome Associated with Atypical Antipsychotic Drugs
Trollor, J. N., Chen, X., & Sachdev, P. S. (2009) · CNS Drugs · doi:10.2165/00023210-200923060-00003 · Cited by 155 · see citing works
Severe and Uncommon Involuntary Movement Disorders due to Psychotropic Drugs
Stübner, S., Rustenbeck, E., Grohmann, R., Wagner, G., Engel, R. R., Neundörfer, G., Möller, H., Hippius, H., & Rüther, E. (2004) · Pharmacopsychiatry · doi:10.1055/s-2004-815511 · Cited by 116 · see citing works
Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal
Shiovitz, T. M., Welke, T. L., Tigel, P. D., Anand, R., Hartman, R. D., Sramek, J. J., Kurtz, N. M., & Cutler, N. R. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.4.591 · Cited by 104 · see citing works
Case-control study of neuroleptic malignant syndrome
Sachdev, P. S., Mason, C., & Hadži-Pavlović, D. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.8.1156 · Cited by 99 · see citing works
Atypical Neuroleptic Malignant Syndrome: Diagnostic Controversies and Considerations
Picard, L. S., Lindsay, S., Strawn, J. R., et al. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.4.530 · Cited by 87 · see citing works
Proposed research diagnostic criteria for neuroleptic malignant syndrome
Mathews, T., & Aderibigbe, Y. A. (1999) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001388 · Cited by 65 · see citing works
Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment
Спивак, Б., Weizman, A., Wolovick, L., et al. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb06473.x · Cited by 60 · see citing works
Clozapine Withdrawal Catatonia and Neuroleptic Malignant Syndrome: a Case Report
Lee, J. J., & Robertson, S. (1997) · Annals of Clinical Psychiatry · doi:10.3109/10401239709147792 · Cited by 50 · see citing works
Withdrawal reactions associated with venlafaxine
Parker, G., & Blennerhassett, J. (1998) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048679809062742 · Cited by 45 · see citing works
Neuroleptic malignant syndrome after neuroleptic discontinuation
Amore, M., & Zazzeri, N. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(95)00269-3 · Cited by 42 · see citing works
Odagaki, Y. (2009) · Current Drug Safety · doi:10.2174/157488609787354387 · Cited by 41 · see citing works
Neuroleptic malignant syndrome and clozapine withdrawal at the same time?
Margetić, B., & Aukst‐Margetić, B. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.10.001 · Cited by 24 · see citing works
Howland, R. H. (2010) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20100506-01 · Cited by 22 · see citing works
Psychotropic discontinuation symptoms: a case of withdrawal neuroleptic malignant syndrome
Stonecipher, A., Galang, R. L., & Black, J. (2006) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2006.07.007 · Cited by 12 · see citing works
Venlafaxine withdrawal syndrome.
Sabljić, V., Ružić, K., & Rakun, R. (2011) · PubMed · Cited by 11 · see citing works
Delayed Onset of Neuroleptic Malignant Syndrome after Discontinuation of Thioridazine
Kasckow, J., Dolor, R. J., & Lipper, S. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199004000-00027 · Cited by 7 · see citing works
Neuroleptic malignant syndrome (NMS) on neuroleptic withdrawal
Corrigan, F. M., Coulter, F., & Mackay, A. V. P. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb03067.x · Cited by 3 · see citing works
Parkinson disease and Neuroleptic withdrawal
Jambunathan, S. T., Gil, J., Koh, O. H., et al. (2010) · Annals of General Psychiatry · doi:10.1186/1744-859x-9-s1-s223 · Cited by 1 · see citing works
Neuroleptic–malignant syndrome
MacKenzie, J. (1986) · Anaesthesia · doi:10.1111/j.1365-2044.1986.tb13288.x · Cited by 1 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- Ball H, de Waal H, Craig K. An unrecognised case of withdrawal neuroleptic malignant syn- drome: a case report. Medicine Science and the Law 2009;49:298-300.
- Levenson JL. Neuroleptic malignant syn- drome. Am J Psychiatry 1985;142:1137-45.
- Sablji V, Rui K, Rakun R. Venlafaxine with- drawal syndrome. Psychiatria Danubina 2011;23(1):117-9.
- 1931227x, 2013, 5, Downloaded from https://wchh.onlinelibrary.wiley.com/doi/10.1002/pnp.297 by Readcube (Labtiva Inc.), Wiley Online Library on [15/08/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License · DOI
Cited by
Sorted by citations
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157 · see citing works
- Authors
- Kurien, R., & Vattakatuchery, J. J.
- Venue
- Progress in Neurology and Psychiatry
- Publisher
- Wiley
- Published
- 2013-09
- Volume
- 17
- Issue
- 5
- Pages
- 8-10
- ISSN
- 1367-7543 (ISSN-L)
- 1931-227X
- OpenAlex
- W1983861431
- Cited by
- 6
- References
- 21
- Citations by year
- 2023: 3 · 2022: 1 · 2021: 1 · 2017: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Progress in Neurology and Psychiatry (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Historical Psychiatry and Medical Practices
- Keywords
- neuroleptic malignant syndrome, clozapine, venlafaxine, paranoid schizophrenia, antipsychotic adverse effects, drug withdrawal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
